Donald E. Cutlip

“

The post hoc analysis strongly supports a benefit for the Tryton Stent in the intended population. The results are hypothesis generating, to be supported by further analysis.

Robert W. Yeh

Interventional cardiologist, Beth Israel Deaconess Medical Center · Beth Israel Deaconess Medical Center

2mo

“

Dual antiplatelet therapy is standard for patients following coronary stent procedures, but we haven't had good tools to help us determine how long we should be treating individual patients.

David E. Kandzari

Interventional cardiologist, Piedmont Heart Institute · Piedmont Heart Institute

2mo

“

To our knowledge, this is the only trial that has demonstrated superiority [of a new stent] to the Xience drug-eluting stent in a large, randomized trial. This is a landmark in interventional cardiology that raises the bar for future comparisons

Heerajnarain Bulluck

Cardiologist, Norwich University Hospital, England · Norwich University Hospital

2mo

“

There is a lot of debate and controversy about how we best define type 4a MIs, with previous studies like EXCEL and ISCHEMIA using their own definitions. Depending on the definition used, this can change the outcomes of these trials quite significantly.

Philippe Généreux

Interventional cardiologist, Morristown Medical Center · Morristown Medical Center

3mo

“

VARC-3 has, I would say, the most-contemporary definitions for aortic valve replacement-related research for both procedural complications, mid-term outcomes, and long-term outcomes, including outcomes related to valve function and patient-centric outcomes. I believe it's a really good document that reflects the last 10 years of progress in the field. We put in a lot of time and effort to come up with clinically meaningful definitions to better classify outcomes and design relevant research.

“

We developed a standardized vocabulary for documenting and reporting critical cardiovascular adverse events, along with specifications for the exchange of that information between computer systems. The key use will be in reporting findings to the FDA, whether in the context of clinical trials, pharmacovigilance, or device surveillance. Ultimately, we anticipate widespread adoption of this vocabulary throughout healthcare (including routine clinical care) as a catalyst for accelerating improvements in patient management and treatment.

“

We developed a standardized vocabulary for documenting and reporting critical cardiovascular adverse events, along with specifications for the exchange of that information between computer systems. The key use will be in reporting findings to the FDA, whether in the context of clinical trials, pharmacovigilance, or device surveillance. Ultimately, we anticipate widespread adoption of this vocabulary throughout healthcare (including routine clinical care) as a catalyst for accelerating improvements in patient management and treatment.